Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Receivables - Other (2019 - 2025)

Historic Receivables - Other for Neurocrine Biosciences (NBIX) over the last 6 years, with Q4 2025 value amounting to $20.5 million.

  • Neurocrine Biosciences' Receivables - Other rose 4236.11% to $20.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $20.5 million, marking a year-over-year increase of 4236.11%. This contributed to the annual value of $20.5 million for FY2025, which is 4236.11% up from last year.
  • Per Neurocrine Biosciences' latest filing, its Receivables - Other stood at $20.5 million for Q4 2025, which was up 4236.11% from $14.4 million recorded in Q4 2024.
  • Neurocrine Biosciences' Receivables - Other's 5-year high stood at $20.5 million during Q4 2025, with a 5-year trough of $2.7 million in Q2 2021.
  • Over the past 4 years, Neurocrine Biosciences' median Receivables - Other value was $6.8 million (recorded in 2023), while the average stood at $8.5 million.
  • Per our database at Business Quant, Neurocrine Biosciences' Receivables - Other tumbled by 3191.49% in 2021 and then soared by 18636.36% in 2024.
  • Neurocrine Biosciences' Receivables - Other (Quarter) stood at $2.8 million in 2021, then soared by 300.0% to $11.2 million in 2023, then increased by 28.57% to $14.4 million in 2024, then surged by 42.36% to $20.5 million in 2025.
  • Its last three reported values are $20.5 million in Q4 2025, $14.4 million for Q4 2024, and $12.6 million during Q1 2024.